PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Despite an Insulet stake reduction by a major fund, analysts maintain a 'Moderate Buy' rating. Discover why institutional ...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market ...

Get the latest U.S. stock market and healthcare sector updates, key company news, and top healthcare winners and losers.

Despite record beef prices linked to a country-wide cattle shortage, long lines formed at butcher shops Tuesday. TMJ4 spoke with some in line to hear how the price hike is affecting their wallets.

Explore MiniMed Group, Inc.'s upcoming IPO, market position in diabetes devices, and key financial risks. Click for this MMED ...

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s ...

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with ...

Fintel reports that on December 18, 2025, Truist Securities maintained coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 31.68% Upside As of December 5, ...

Fintel reports that on December 16, 2025, Evercore ISI Group initiated coverage of Insulet (NasdaqGS:PODD) with a Outperform recommendation. Analyst Price Forecast Suggests 33.61% Upside As of ...

In a report released on December 16, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed yesterday at $288.73.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...